Chronic Lymphocytic Leukemia
📧 Sign up to get email alerts when something new happens for Chronic Lymphocytic Leukemia.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-02-05Clinical Trial Update: HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis [Phase 2]
Phase 2 clinical trial evaluating reduced-dose post-transplant cyclophosphamide as GVHD prophylaxis in HLA-mismatched unrelated donor periph…
-
CLINICAL_TRIALS research · 2026-02-02Clinical Trial Update: Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL) [Phase 1]
Phase 1 dose-escalation and dose-expansion study to evaluate the safety of Azer-cel (PBCAR0191) in relapsed/refractory non-Hodgkin lymphoma …
-
CLINICAL_TRIALS research · 2026-01-30Clinical Trial Update: Expanded Access to Venetoclax
Expanded access to venetoclax is being offered for multiple hematologic cancers, including chronic lymphocytic leukemia, multiple myeloma, A…
-
CLINICAL_TRIALS research · 2026-01-29Clinical Trial Update: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) [Phase 3]
Phase 3 trial comparing Pirtobrutinib plus Venetoclax and Rituximab (PVR) versus Venetoclax and Rituximab (VR) in previously treated chronic…
-
CLINICAL_TRIALS research · 2026-01-29Clinical Trial Update: Assessing Minimal Residual Disease by Next- Generation Sequencing to Minimize Exposure in People With CLL or SLL Who Have Been Treated With Venetoclax [Phase 2]
Phase 2 clinical trial evaluating minimal residual disease assessment by next-generation sequencing to minimize exposure in patients with ch…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic Neoplasms
Clinical trial registry update for the RUBIN platform extension focusing on hematologic malignancies. It is currently recruiting for conditi…
-
CLINICAL_TRIALS research · 2026-01-28Clinical Trial Update: Digital Health Intervention for Self-Management and Telemonitoring in Chimeric Antigen Receptor (CAR-T) Therapy [Phase 3]
Phase 3 clinical trial evaluating a digital health intervention for self-management and telemonitoring in CAR-T therapy is currently recruit…
-
CLINICAL_TRIALS research · 2026-01-27Clinical Trial Update: Combination of Lenalidomide and Rituximab in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL-SLL) [Phase 2]
A Phase 2 trial evaluating the combination of lenalidomide and rituximab in chronic lymphocytic leukemia/small lymphocytic lymphoma is curre…
-
CLINICAL_TRIALS research · 2026-01-22Clinical Trial Update: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) [Phase 3]
A Phase 3 clinical trial comparing pirtobrutinib to bendamustine plus rituximab in untreated chronic lymphocytic leukemia/small lymphocytic …
-
CLINICAL_TRIALS research · 2026-01-22Clinical Trial Update: Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
Clinical trial update describing a Bristol-Myers Squibb-sponsored study to perform transgene assay testing on tumor samples from patients wh…
-
CLINICAL_TRIALS research · 2026-01-21Clinical Trial Update: CLL Therapy Approaches in Russia
AstraZeneca-sponsored clinical trial activity for Chronic Lymphocytic Leukemia in Russia is listed as ACTIVE_NOT_RECRUITING.
-
CLINICAL_TRIALS research · 2026-01-21Clinical Trial Update: Fixed Duration Pirtobrutinib and Obinutuzumab in Chronic Lymphocytic Leukemia [Phase 2]
A Phase 2 trial investigating a fixed-duration regimen of pirtobrutinib plus obinutuzumab in chronic lymphocytic leukemia or small lymphocyt…
-
CLINICAL_TRIALS research · 2026-01-20Clinical Trial Update: Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. [Phase 1]
Phase 1 study evaluating T cells engineered to co-express kappa and CD28 CARs for relapsed/refractory kappa+ non-Hodgkin lymphoma and chroni…
-
CLINICAL_TRIALS research · 2026-01-16Clinical Trial Update: A Study to Assess the Adverse Events, Change in Disease Activity, and How Intravenously Infused ABBV-319 Moves Through the Bodies of Adult Participants With Relapsed or Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL), Follicular Lymphoma (FL), or Chronic Lymphocytic Leukemia (CLL) [Phase 1]
Phase 1 clinical trial update for ABBV-319 evaluating adverse events, change in disease activity, and pharmacokinetics in adults with relaps…
-
CLINICAL_TRIALS research · 2026-01-13Clinical Trial Update: Reticulocyte Parameters as Early Indicators of Bone Marrow Erythropoietic Activity in Chronic B Lymphoproliferative Neoplasms
This clinical trial investigates reticulocyte parameters as early indicators of bone marrow erythropoietic activity in chronic B-cell lympho…
-
CLINICAL_TRIALS research · 2026-01-12Clinical Trial Update: A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies [Phase 1]
A Phase 1 clinical trial evaluating UB-VV111 with and without rapamycin for relapsed/refractory CD19+ B-cell malignancies is currently recru…
-
CLINICAL_TRIALS research · 2026-01-07Clinical Trial Update: Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL [Phase 3]
A Phase 3 trial is evaluating adding Sonrotoclax to Zanubrutinib for patients with previously untreated chronic lymphocytic leukemia or smal…
-
CLINICAL_TRIALS research · 2026-01-07Clinical Trial Update: Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation [Phase 2]
Phase 2 clinical trial evaluating glofitamab as monotherapy and in combination with polatuzumab vedotin, pirtobrutinib, or atezolizumab for …
-
CLINICAL_TRIALS research · 2026-01-07Clinical Trial Update: Safe Accelerated Venetoclax Escalation in CLL [Phase 1]
Phase 1 trial update reporting safe accelerated venetoclax escalation in chronic lymphocytic leukemia and small lymphocytic lymphoma.
-
CLINICAL_TRIALS research · 2026-01-07Clinical Trial Update: Daratumumab and Ibrutinib in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia [Phase 1]
This document provides an update on a Phase 1 clinical trial investigating the combination of daratumumab and ibrutinib to treat symptomatic…
-
CLINICAL_TRIALS research · 2026-01-06Clinical Trial Update: Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL [Phase 2]
Phase 2 trial evaluating intermittent versus continuous venetoclax in combination with acalabrutinib for chronic lymphocytic leukemia and sm…
-
CLINICAL_TRIALS research · 2026-01-06Clinical Trial Update: REtreatment With VEnetoclax and Acalabrutinib After Venetoclax Limited Duration (REVEAL) [Phase 2]
Phase 2 trial REVEAL evaluates retreatment with venetoclax plus acalabrutinib after a limited duration of venetoclax in patients with CLL/SL…
-
CLINICAL_TRIALS research · 2026-01-06Clinical Trial Update: Study of Epcoritamab as a Consolidation Therapy in CLL/SLL [Phase 2]
Phase 2 study evaluating epcoritamab as consolidation therapy for chronic lymphocytic leukemia/small lymphocytic lymphoma is currently recru…
-
CLINICAL_TRIALS research · 2026-01-05Clinical Trial Update: Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) [Phase 1]
Phase 1 trial evaluating activated T cells expressing second- or third-generation CD19-directed CAR-T cells in advanced B-cell malignancies.…
-
CLINICAL_TRIALS research · 2026-01-02Clinical Trial Update: LEF1 EXPRESSION IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS: A MARKER FOR DIAGNOSIS AND SURVIVAL PREDICTION
This clinical trial is currently recruiting to evaluate LEF1 expression in B-cell chronic lymphocytic leukemia and small lymphocytic lymphom…